Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The market is growing because genetic illnesses are becoming more common, especially in newborns. The introduction of new and improved pharmaceuticals to treat the symptoms and aftereffects of the disease, along with an increase in research and development expenditures aimed at developing novel treatment approaches to cure the genetic disorder, are anticipated to propel market expansion. High demand for novel treatments tailored to specific diseases may expand the market. The launch of drugs to address complications associated with GM2 Gangliosidosis is driving the market's expansion.